Tiziana Life Sciences Ltd (TLSA)
NASDAQ: TLSA · Real-Time Price · USD
2.330
+0.040 (1.75%)
At close: Aug 6, 2025, 4:00 PM
2.210
-0.120 (-5.15%)
After-hours: Aug 6, 2025, 6:27 PM EDT
Verve Therapeutics Employees
Tiziana Life Sciences had 9 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
9
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,318,111
Market Cap
259.71M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 9 | 0 | - |
Dec 31, 2023 | 9 | 0 | - |
Dec 31, 2022 | 9 | -5 | -35.71% |
Dec 31, 2021 | 14 | 3 | 27.27% |
Dec 31, 2020 | 11 | 3 | 37.50% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
TLSA News
- 16 days ago - Tiziana Life Sciences Announces Immunologic Analysis of Nasal Foralumab in Moderate Alzheimer's Patient - GlobeNewsWire
- 7 weeks ago - Tiziana: Scope Of Foralumab Goes Beyond That Of Multiple Sclerosis Targeting - Seeking Alpha
- 7 weeks ago - Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center - GlobeNewsWire
- 7 weeks ago - Tiziana Life Sciences to Present at the Bio International Convention - GlobeNewsWire
- 2 months ago - Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer's Disease - GlobeNewsWire
- 2 months ago - Journal of Clinical Nuclear Medicine Publishes Results of Tiziana's Nasal Foralumab in Study Treating Moderate Alzheimer's Disease - GlobeNewsWire
- 3 months ago - Tiziana Life Sciences Announces Purchase of Shares by Chairman - GlobeNewsWire
- 3 months ago - Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab - GlobeNewsWire